Each tablet contains sotalol HCL 80 mg.
Sotalol hydrochloride has class II and III anti-arrhythmic properties and non selective adrenergic beta receptor blocking action.
Sotalol hydrochloride (Betacor®) has two main actions;
1-Beta-blocking action with class II antiarrhythmic property, it increases sinus cycle length (slows heart rate), decreases A V nodal conduction and increases A V nodal refractoriness.
2-Class III antiarrhythmic action; it prolongs atrial and ventricular action potentials and prolongs the atrial and ventricular refractory periods, through blocking potassium channels (phase 3).
Sotalol hydrochloride (Betacor®) is completely absorbed after oral administration and has an absolute bioavailability of 100%.Peak plasma levels occur within 2-3 hours after oral intake. Plasma protein binding is about 35%. Sotalol hydrochloride is excreted mostly unchanged in urine and the elimination half-life ranges from 7-18 hours which is increased in the elderly and in renal failure. Sotalol hydrochloride can cross the placenta and is excreted in breast milk.
- Sustained ventricular tachycardia
- Ventricular tachyarrhythmias
- Paroxysmal supraventricular tachycardia
- Wolff-Parkinson White syndrome (WPW syndrome)
- Recurrence of atrial fibrillation
- Angina pectoris and essential hypertension
May be present due to its ß-blocking action, e.g., hypotension, bradycardia and conduction disturbances in A V node.
The recommended oral dose of (Betacor®) is 160 mg once daily or 80 mg twice daily. This dose may be increased up to 480 mg/day for emergency treatment of cardiac arrhythmias.
Strips of 10 tablets in packs of 1 strip or 3 strips.
Keep all medicaments out of reach of children
Product of: AMOUN PHARMACEUTICAL CO. El-Obour City, Cairo, Egypt. ATC Code: C07AA07